Antidepressant discontinuation and risk of suicide attempt: A retrospective, nested case-control study

Journal of Clinical Psychiatry

Volumn 70, Issue 8, 2009, Pages 1069-1077

  Valuck, Robert J ^a   Orton, Heather D ^b   Libby, Anne M ^b  

^a UNIVERSITY OF COLORADO   (United States)

^b UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

SEROTONIN NORADRENALIN REUPTAKE INHIBITOR; SEROTONIN UPTAKE INHIBITOR; TRICYCLIC ANTIDEPRESSANT AGENT; ANTIDEPRESSANT AGENT;

ADOLESCENT; ADULT; AGED; ARTICLE; CHILD; CONTROLLED STUDY; DATA BASE; DEPRESSION; FEMALE; HOSPITAL PATIENT; HUMAN; MAJOR CLINICAL STUDY; MALE; PRESCHOOL CHILD; PRIORITY JOURNAL; RISK ASSESSMENT; SCHOOL CHILD; SUICIDE ATTEMPT; TITRIMETRY; TREATMENT DURATION; CASE CONTROL STUDY; COHORT ANALYSIS; COMPARATIVE STUDY; DOSE RESPONSE; DRUG ADMINISTRATION; EPIDEMIOLOGY; HOSPITALIZATION; LONGITUDINAL STUDY; MAJOR DEPRESSION; MIDDLE AGED; PSYCHOLOGICAL ASPECT; RETROSPECTIVE STUDY; RISK FACTOR; STATISTICS; UNITED STATES; WITHDRAWAL SYNDROME;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIDEPRESSIVE AGENTS; CASE-CONTROL STUDIES; CHILD; CHILD, PRESCHOOL; COHORT STUDIES; CONFOUNDING FACTORS (EPIDEMIOLOGY); DEPRESSIVE DISORDER, MAJOR; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; HUMANS; LONGITUDINAL STUDIES; MIDDLE AGED; RETROSPECTIVE STUDIES; RISK FACTORS; SEVERITY OF ILLNESS INDEX; SUBSTANCE WITHDRAWAL SYNDROME; SUICIDE, ATTEMPTED; UNITED STATES;

EID: 70349564376     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: 10.4088/JCP.08m04943     Document Type: Article

References (20)

1. Posner K, Oquendo M, Gould M, et al. Columbia Classification Algorithm of Suicide Assessment (C-CASA): classification of suicidal events in the FDA's pediatric suicidal risk analysis of antidepressants. Am J Psychiatry. 2007;164(7):1035-1043. PubMed doi:10.1176/appi.ajp.164.7.1035 (Pubitemid 47121392)
2. US Food and Drug Administration. FDA Updates Its Review of Antidepressant Drugs in Children [FDA Talk Paper]. http://www.fda.gov/bbs/topics/ANSWERS/2004/ ANS01306.html. Published August 20, 2004. Accessed August 20, 2004.
3. US Food and Drug Administration. FDA reviews data for antidepressant use in adults [FDA Talk Paper]. Published July 1, 2005. http://www.fda.gov/bbs/ topics/ANSWERS/2005/ANS01362.html. Accessed December 8, 2005.
4. Bridge JA, Iyengar S, Salary CB, et al. Clinical response and risk for reported suicidal ideation and suicide attempts in pediatric antidepressant treatment: a meta-analysis of randomized controlled trials. JAMA. 2007;297(15):1683-1696. PubMed doi:10.1001/jama.297.15.1683 (Pubitemid 46631627)
5. Hammad TA, Laughren T, Racoosin J. Suicidality in pediatric patients treated with antidepressant drugs. Arch Gen Psychiatry. 2006;63(3):332-339. PubMed doi:10.1001/archpsyc.63.3.332 (Pubitemid 43345358)
6. Klein DF. The flawed basis for FDA postmarketing safety decisions: the example of antidepressants and children. Neuropsychopharmacology. 2006;31(4):689-699. PubMed doi:10.1038/sj.npp.1300996
7. Simon GE, Savarino J. Suicide attempts among patients starting depression treatment with medications or psychotherapy. Am J Psychiatry. 2007;164(7):1029-1034. PubMed doi:10.1176/appi.ajp.164.7.1029 (Pubitemid 47121391)
8. Valuck RJ, Libby AM, Sills MR, et al. Antidepressant treatment and risk of suicide attempt by adolescents with major depressive disorder: a propensity-adjusted retrospective cohort study. CNS Drugs. 2004;18(15):1119- 1132. PubMed doi:10.2165/00023210-200418150-00006
9. National Committee for Quality Assurance. The State of Health Care Quality: 2005. http://www.ncqa.org/Docs/SOHCQ-2005.pdf. Accessed December 9, 2005.
10. Scholle SH. NCQA behavioral health measurement efforts. J Manag Care Pharm. 2005;11(3):S9-S11. PubMed
11. O'Carroll PW, Potter LB. Centers for Disease Control and Prevention. Suicide Contagion and the Reporting of Suicide: Recommendations from a National Workshop. http://www.cdc.gov/mmwr/preview/mmwrhtml/00031539.htm. Published April 22, 1994. Accessibility verified April 30, 2009.
12. Valuck RJ, Libby AM, Benton T, et al. A descriptive analysis of 10,000 suicide attempters in United States managed care plans, 1998-2005. Prim Psychiatry. 2007;14(11):52-60.
13. Malone DC, Billups SJ, Valuck RJ, et al for the IMPROVE Investigators. Development of a chronic disease indicator score using a Veterans Affairs Medical Center medication database. J Clin Epidemiol. 1999;52(6):551-557. PubMed doi:10.1016/S0895-4356(99)00029-3
14. Berard A, Azoulay L, Koren G, et al. Isotretinoin, pregnancies, abortions and birth defects: a population-based perspective. Br J Clin Pharmacol. 2007;63(2):196-205. PubMed doi:10.1111/j.1365-2125.2006.02837.x (Pubitemid 46072106)
15. US Food and Drug Administration. Information for healthcare professionals: suicidality and antiepileptic drugs. http://www.fda.gov/cder/ drug/InfoSheets/HCP/antiepilepticsHCP.htm. Published January 31, 2008. Accessed January 31, 2008.
16. Libby AM, Brent DA, Morrato EH, et al. Decline in treatment of pediatric depression after FDA advisory on risk of suicidality with SSRIs. Am J Psychiatry. 2007;164(6):884-891. PubMed doi:10.1176/appi.ajp.164.6.884
17. US Food and Drug Administration. FDA proposes new warnings about suicidal thinking, behavior in young adults who take antidepressant medications [FDA news]. http://www.fda.gov/bbs/topics/NEWS/2007/NEW01624.html. Published May 2, 2007. Accessed September 12, 2007.
18. SAS Institute Inc. SAS Language, Version 9.1. Cary, NC: SAS Institute; 2004.
19. Simon GE, Savarino J, Operskalski B, et al. Suicide risk during antidepressant treatment. Am J Psychiatry. 2006;163(1):41-47. PubMed doi:10.1176/appi.ajp.163.1.41
20. Baldessarini RJ, Tondo L, Strombom IM, et al. Ecological studies of antidepressant treatment and suicidal risks. Harv Rev Psychiatry. 2007;15(4):133-145. PubMed doi:10.1080/10673220701551102 (Pubitemid 47237774)